115563
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
速效救心丸通过 ST2L 信号通路增强调节性 T 细胞功能促进心肌梗死后心脏修复
Authors Zhang L, Guo Y, Fan Y, Liu T, Wang T, Li M, Wang S , Yu Q , Wang H
Received 1 August 2025
Accepted for publication 28 December 2025
Published 6 January 2026 Volume 2026:19 557620
DOI https://doi.org/10.2147/JIR.S557620
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Dr Rongxue Wu
Lusha Zhang,1– 3,* Ying Guo,1,* Yuming Fan,1 Ting Liu,1 Tianyu Wang,1 Mengyao Li,1 Shaoxia Wang,1 Qi Yu,2 Hong Wang1
1School of Medical Technology, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, People’s Republic of China; 2Shaanxi Key Laboratory of Ischemic Cardiovascular Diseases and Institute of Basic and Translational Medicine, Xi’an Medical University, Xi’an, 710021, People’s Republic of China; 3Graduated School, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Hong Wang, School of Medical Technology, Tianjin University of Traditional Chinese Medicine, 10 Poyanghu Road, West Area, Tuanbo New Town, Jinghai District, Tianjin, 301617, People’s Republic of China, Tel +862259596171, Email wanghongsys@tjutcm.edu.cn Qi Yu, Shaanxi Key Laboratory of Ischemic Cardiovascular Diseases and Institute of Basic and Translational Medicine, Xi’an Medical University, 1, Xinwang Road, Weiyang District, Xi ‘An, 710021, People’s Republic of China, Email qiyu6028@hotmail.com
Background: Clinical evidence suggests that extended treatment with Suxiao Jiuxin Pill (SJP) significantly reduces the recurrence rates of myocardial infarction (MI), primarily through its modulation of cardiac immune-fibrotic responses. Nonetheless, the precise molecular mechanisms underlying this effect remain to be fully elucidated.
Methods: Male C57BL/6J mice were randomly assigned to six groups: sham-operated control, MI + saline (vehicle control), MI + SJP (39, 78, and 156 mg/kg), and MI + dapagliflozin (1.5 mg/kg, positive control). Cardiac function and infarct size were assessed using echocardiography and Masson’s trichrome staining. Serum levels of lactate dehydrogenase (LDH), creatine kinase (CK), and creatine kinase-MB (CK-MB) were measured with a Hitachi 7020 automatic biochemical analyzer, while cardiac troponin T (cTnT) levels were quantified via enzyme-linked immunosorbent assay (ELISA). Gene expression analysis was conducted using reverse transcription polymerase chain reaction (RT-PCR). Immune cell populations within the ischemic heart were analyzed through flow cytometry. Naïve CD4+ T cells were isolated and differentiated into regulatory T cells (Tregs) to assess their immunosuppressive function.
Results: The administration of SJP treatment resulted in a significant reduction in infarct size and enhancement of cardiac function in mice with MI. Additionally, SJP modulated the immune profile of the infarcted myocardium by reducing neutrophil infiltration and increasing the presence of CD4+ T cells and CD206+ macrophages. Importantly, SJP markedly expanded the population of regulatory T cells (Tregs) and augmented their immunosuppressive capabilities, as evidenced by the upregulated expression of IL-10, Ctla-4, and Sparc. The cardioprotective effects of SJP were found to be dependent on Tregs, as their depletion negated the therapeutic benefits of SJP. Mechanistically, SJP facilitated Treg expansion within the infarcted myocardium by activating the ST2L/Foxp3 signaling pathway and restoring the balance between Treg and Th17 cytokines. In vitro analyses identified senkyunolide I and levistolide A as the predominant active compounds responsible for these effects.
Conclusion: This study elucidates the cardioprotective effects of SJP, which are mediated through the expansion of the Treg population and enhancement of their immunosuppressive function via activation of the ST2L/Foxp3 signaling pathway, with senkyunolide I and levistolide A identified as primary drivers behind the enhanced Treg function.
Keywords: Suxiao Jiuxin pill, myocardial infarction, ST2L, Treg
1School of Medical Technology, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, People’s Republic of China; 2Shaanxi Key Laboratory of Ischemic Cardiovascular Diseases and Institute of Basic and Translational Medicine, Xi’an Medical University, Xi’an, 710021, People’s Republic of China; 3Graduated School, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Hong Wang, School of Medical Technology, Tianjin University of Traditional Chinese Medicine, 10 Poyanghu Road, West Area, Tuanbo New Town, Jinghai District, Tianjin, 301617, People’s Republic of China, Tel +862259596171, Email wanghongsys@tjutcm.edu.cn Qi Yu, Shaanxi Key Laboratory of Ischemic Cardiovascular Diseases and Institute of Basic and Translational Medicine, Xi’an Medical University, 1, Xinwang Road, Weiyang District, Xi ‘An, 710021, People’s Republic of China, Email qiyu6028@hotmail.com
Background: Clinical evidence suggests that extended treatment with Suxiao Jiuxin Pill (SJP) significantly reduces the recurrence rates of myocardial infarction (MI), primarily through its modulation of cardiac immune-fibrotic responses. Nonetheless, the precise molecular mechanisms underlying this effect remain to be fully elucidated.
Methods: Male C57BL/6J mice were randomly assigned to six groups: sham-operated control, MI + saline (vehicle control), MI + SJP (39, 78, and 156 mg/kg), and MI + dapagliflozin (1.5 mg/kg, positive control). Cardiac function and infarct size were assessed using echocardiography and Masson’s trichrome staining. Serum levels of lactate dehydrogenase (LDH), creatine kinase (CK), and creatine kinase-MB (CK-MB) were measured with a Hitachi 7020 automatic biochemical analyzer, while cardiac troponin T (cTnT) levels were quantified via enzyme-linked immunosorbent assay (ELISA). Gene expression analysis was conducted using reverse transcription polymerase chain reaction (RT-PCR). Immune cell populations within the ischemic heart were analyzed through flow cytometry. Naïve CD4+ T cells were isolated and differentiated into regulatory T cells (Tregs) to assess their immunosuppressive function.
Results: The administration of SJP treatment resulted in a significant reduction in infarct size and enhancement of cardiac function in mice with MI. Additionally, SJP modulated the immune profile of the infarcted myocardium by reducing neutrophil infiltration and increasing the presence of CD4+ T cells and CD206+ macrophages. Importantly, SJP markedly expanded the population of regulatory T cells (Tregs) and augmented their immunosuppressive capabilities, as evidenced by the upregulated expression of IL-10, Ctla-4, and Sparc. The cardioprotective effects of SJP were found to be dependent on Tregs, as their depletion negated the therapeutic benefits of SJP. Mechanistically, SJP facilitated Treg expansion within the infarcted myocardium by activating the ST2L/Foxp3 signaling pathway and restoring the balance between Treg and Th17 cytokines. In vitro analyses identified senkyunolide I and levistolide A as the predominant active compounds responsible for these effects.
Conclusion: This study elucidates the cardioprotective effects of SJP, which are mediated through the expansion of the Treg population and enhancement of their immunosuppressive function via activation of the ST2L/Foxp3 signaling pathway, with senkyunolide I and levistolide A identified as primary drivers behind the enhanced Treg function.
Keywords: Suxiao Jiuxin pill, myocardial infarction, ST2L, Treg